Chemokine networks in inflammatory skin diseases

European Journal of Dermatology

Volumn 14, Issue 4, 2004, Pages 203-208

  Pastore, Saveria ^a   Mascia, Francesca ^a   Mariotti, Feliciana ^a   Dattilo, Cristina ^a   Girolomoni, Giampiero ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Allergic contact dermatitis; Atopic dermatitis; Chemokine receptors; Chemokines; Psoriasis

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR; EOTAXIN; FRACTALKINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; PULMONARY AND ACTIVATION REGULATOR CHEMOKINE; RANTES; T LYMPHOCYTE SECRETED PROTEIN I 309; THYMUS AND ACTIVATION REGULATOR CHEMOKINE; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; HUMAN; LEUKOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PSORIASIS; REVIEW; SKIN ALLERGY; SKIN CELL; SKIN INFLAMMATION;

DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; HUMANS; PSORIASIS; RECEPTORS, CHEMOKINE; SKIN DISEASES;

EID: 3543077154     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003; 121: 951-62.
2. Chong BF, Murphy JE, Kupper TS, Fuhlbrigge RC. E-selectine, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol 2004; 172: 1575-81.
3. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 75-84.
4. Sallusto F, Mackay CF, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18: 593-620.
5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 2: 121-7.
6. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
7. Kunkel EJ, and Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16: 1-4.
8. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14: 129-35.
9. Struyf S, Proost P, Van Damme J. Regulation of the immune response by the interaction of chemokines and proteases. Adv Immunol 2003; 81: 1-44.
10. 3 C motif. Nature 1997; 385: 640-4.
11. Sallusto F, Kremmer E, Palermo B, Hoy A, Ponath P, Qin S, Forster R, Lipp M, Lanzavecchia A. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999; 29: 2037-45.
12. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-7.
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
14. Mellado M, Rodriguez-Frade JM, Moñes S, Mortínez A-C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 2001; 19: 397-421.
15. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldhom E, Zlotnik A. The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000; 164: 3465-70.
16. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP, Warnke R, Ruffing N, Kossam N, Wu L, Butcher EC. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400: 776-80.
17. Loetscher P, Pellegrino A, Gong J-H, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I. The ligands of CXC receptor 3, I-TAC, Mig, and IP-10 are natural antagonists for CCR3. J Biol Chem 2001; 276: 2986-91.
18. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001; 97: 1920-4.
19. Sozzoni S, Allavena P, Vecchi A, Mantovoni A. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Clin Immunol 2000; 20: 151-60.
20. Rennert PD, Hochman PS, Flavell RA, Chaplin DD, Jayaraman S, Browning JL, Fu Y-X. Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-α-deficient mice. J Exp Med 2001; 193: 1227-38.
21. Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33.
22. Gunn MD, Kyuwo S, Tam C, Kakiuchi T, Matsukowa A, Williams LT, Nakano H. Mice locking expression of secondary lymphoid organ chemokine hove defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189: 451-60.
23. Girolomoni G, Sebastiani S, Albonesi C, Covani A. T-cell subpopulations in the development of atopic ond contact allergy. Curr Opin Immunol 2001; 13: 733-7.
24. Covani A, Ottavioni C, Nasorri F, Sebastiani S, Girolomoni G. Immunoregulation of hopten ond drug induced immune reactions. Curr Opin Allergy Clin Immunol 2003; 3: 243-7.
25. + T cells as key regulators of immune responses. Eur J Dermatol 2003; 13: 111-6.
26. Goebeler M, Troutmann A, Voss A, Bröcker E-B, Toksoy A, Gillitzer R. Differential and sequential expression of multiple chemokines during elicitation of allergic contact hypersensitivity. Am J Pathol 2001; 158: 431-40.
27. Nakomura K, Williams IR, Kupper TS, Kerotinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 con recruit dendritic and Langerhans cells to skin. J Invest Dermatol 1995; 105: 635-43.
28. Von Andrion UH, Mackoy CR. T-cell function and migrotian. Two sides of the some coin. N Engl J Med 2000; 343: 1020-34.
29. Homey B, Alenius H, Muller A, Soto H, Bowmon EP, Yuon W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, Lehto M, Wolff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-65.
30. Biedermann T, Kneilling M, Moilhammer R, Moier K, Sander CA, Kollias G, Kunkel SL, Hültner L, Röcken M. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441-51.
31. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, De Pità O, Puddu P, Girolomoni G. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. J Immunol 2000; 165: 1395-402.
32. Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S, Girolomoni G. A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Th1 cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol 2001; 70: 617-23.
33. Mascio F, Moriani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-12.
34. + T cells display distinct migratory response to chemokines produced during allergic contact dermatitis. J Invest Dermatol 2002; 118: 1052-8.
35. + T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000; 114: 295-302.
36. + T lymphocytes with regulatory activity. J Immunol 2001; 116: 996-1002.
37. Varona R, Villares R, Carramolino L, Goya I, Zaballos A, Gutierréz J, Torres M, Martinez-A C, Màrquez G. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest 2001; 107: R37-45.
38. Asadullah K, Volk H-D, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002; 23: 47-53.
39. Krueger JG. The immunologic basis for the treatment of psoriasis with new tiological agents. J Am Acad Dermatol 2002; 46: 1-23.
40. Schön MP, and Ruzicka T. Psoriasis: the plot thickens... Nat Immunol 2001; 2: 91.
41. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820-8.
42. Nomuro I, Goo B, Boguniewicz N, Dorst MA, Trovers JB, Leung DYM. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microorray analysis. J Allergy Clin Immunol 2003; 112: 1195-1202.
43. Gillitzer R, Wolff K, Tong D, Müller C, Yoshimura T, Hartmann AA, Stingl G, Berger R. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 1993; 101: 127-31.
44. Gottlieb AB, Luster AD, Posnett DN, Corter DM. Detection of a γ interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988; 168: 941-8.
45. Homey B, Dieu-Nosejon M-C, Wiesenborn A, Massacrier C, Pin J-J, Oldhom E, Catron D, Buchanon ME, Müller A, deWaal Malefyt R, Deng G, Orozco R, Ruzicko T, Lehman P, Lebecque S, Caux C, Zlotnik A. Up-regulation of mocrophage inflammatary protein 3α/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164: 6621-32.
46. Dieu-Nosejon M-C, Massacrier C, Homey B, Vanbervliet B, Pin J-J, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Coux C. Macrophage inflommatory protein 3α is expressed at inflomed epitheliol cell surfaces and is the most potent chemokine known in attracting Langerhons cell precursor. J Exp Med 2000; 192: 705-17.
47. Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG. Potential role of the chemokine receptors CXCR3, CCR4, and the inteqrin αEβ7 in the pothoqenesis of psoriasis vulqaris. Lab Invest 2001; 8: 335-47.
48. Vonbervliet B, Homey B, Durond I, Massacrier C, Ait-Yohia S, de Bouteiller O, Vicari A, Caux C. Sequential involvement of CCR2 and CCR6 ligands for immoture dendritic cell recruitment: possible role at inflomed epithelial surfaces. Eur J Immunol 2002; 32: 231-42.
49. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma Al, Assmann T, Bunemann E, Lehto M, Walff H, Yen D, Marxhausen H, To W, Sedgwick J, Ruzicka T, Lehmann P, Zlotnik A. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-65.
50. D'Ambrosio D, Albanesi A, Lang R, Girolomoni G, Sinigaglia F, Laudanna C. Quantitative differences in chemokine receptor engagement generate diversity in integrin-dependent lymphocyte adhesion. J Immunol 2002; 169: 2303-22.
51. 3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-81.
52. Giustizieri ML, Mascia F, Frezzolini A, De Pità O, Chinni ML, Giannetti A, Girolomoni G, Postore S. Keratinocytes fram patients with atopic dermatitis and psoriasis show a different chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001; 107: 871-7.
53. Giustizieri ML, Albanesi C, Scarponi C, De Pità O, Giralomoni G. Nitric oxide donors suppress chemokine production by keratinocytes in vitra and in vivo. Am J Pathol 2002; 161: 1409-18.
54. Kulke R, Bornscheuer E, Schluter C, Bartels J, Rowert J, Sticherling M, Christophers E. The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatal 1998; 110: 90-4.
55. Sirsjo A, Karlsson M, Gidlaf A, Rollman O, Torma H. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol 1996; 134: 643-8.
56. Ormerad AD, Weller R, Capeland P, Benjamin N, Ralstan SH, Grabowksi P, Herriot R. Detection af nitric oxide and nitric oxide syntheses in psoriasis. Arch Dermatol Res 1998; 290: 3-8.
57. Asadullah K, Friedrich M, Hanneken S, Rohrbach C, Audring H, Vergopaulos A, Ebeling M, Dacke WD, Volk HD, Sterry W. Effects of systemic interleukin-10 therapy on psariatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 2001; 116: 721-7.
58. Reich K, Gorbe C, Blaschke V, Maurer C, Middel P, Westphal G, Lippert U, Neumann C. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, down-regulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001; 116: 319-29.
59. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144: 1114-20.
60. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112: S128-39.
61. Girolomoni G, Pastore S. Epithelial cells and atopic diseases. Curr Allergy Asthma Rep 2001; 1: 481-2.
62. + T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107: 353-8.
63. + T cells reflects disease activity of atopic dermatitis. J Invest Dermatol 2001; 117: 188-96.
64. Vestergaard C, Deleuran M, Gesser B, Gronhoj Larsen C. Expression of the T-helper 2-specific chemokine receptor CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin. Br J Dermatol 2003; 149: 457-63.
65. + T cells from patients with atopic dermatitis: up-regulation of C-C chemokine receptor 4 in atopic dermatitis. Clin Exp Allergy 2002; 32: 1236-42.
66. Fujisawa, T., Fujisawa R, Kata Y, Nakayama T, Morita A, Katsumata H, Nishimori H, Iguchi K, Kamiya H, Gray PW, Chantry D, Suzuki R, Yoshie O. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110: 139-46.
67. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Kamine M, Asahina A, Tamaki K. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol 2002; 27: 270-3.
68. Zheng X, Nakamura K, Furukawa H, Nishibu A, Takahashi M, Tojo M, Kaneko F, Kakinuma T, Tamaki K. Demonstration of TARC and CCR4 mRNA expression and distribution using in situ RT-PCR in the lesional skin of atopic dermatitis. J Dermatol 2003; 30: 26-32.
69. Vulcano M, Albanesi C, Stopacciaro A, Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Del Prete A, Allavena P, Ruco LP, Chiabrando C, Girolomoni G, Mantovani A, Sozzani S. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001; 31: 812-22.
70. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1α, MIP-1β, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 2001; 293: 350-5.
71. Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, Dewald B, Braathen LR, Baggiolini M. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol 1999; 113: 43-8.
72. Schmuth M, Neyer S, Rainer C, Grassegger A, Fritsch P, Romani N, Heufler C. Expression of the C-C chemokine MIP-3α/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002; 11: 135-42.
73. Frezzolini A, Paradisi M, Zaffiro A, Provini A, Cadoni S, Ruffelli M, De Pita O. Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. Allergy 2002; 57: 815-20.
74. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann C. Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. J Allergy Clin Immunol 2002; 109: 681-7.
75. Reich K, Westphal G, König IR, Mössner R, Krüger U, Ziegler A, Neumann C, Schnuch A. Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene. J Allergy Clin Immunol 2003; 112: 1191-4.
76. Kagami S, Kakinuma T, Saeki H, Tsunemi Y, Fujita H, Nakamura K, Takekoshi T, Kishimoto M, Mitsui H, Torii H, Komine M, Asahina A, Tamaki K. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003; 134: 309-13.
77. Pastore S, Fanales-Belasio E, Albanesi C, Chinni ML, Giannetti A, Girolomoni G. Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest 1997; 99: 3009-17.
78. Pastare S, Giustizieri M, Mascia F, Giannetti A, Kaushansky K, Giralomoni G. Dysregulated activation of activator protein 1 in keratinocytes of atopic dermatitis patients with enhanced expression of granulocyte/macrophage-colony stimulating factor. J Invest Dermatol 2000; 115: 1134-43.
79. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang SK. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164: 1612-6.
80. Elliot K, and Forrest S. Genetics of atopic dermatitis. In: Bieber T, Leung DYM, eds. Atopic Dermatitis. New York: Marcel Dekker, 2002; 81-110.
81. Kozma GT, Falus A, Bojszko A, Krikovszky D, Szabo T, Nagy A, Szalai C. Lack of association between atopic eczema/dermatitis syndrome and polymorphisms in the promoter region of RANTES and regulatory region of MCP-1. Allergy 2002; 57: 160-3.
82. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt R, Bazan F, Kastelein RA, Liu YJ. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-80.
83. Elias PM, Woad LC, Feingold KR. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999; 10: 119-26.
84. Mascia F, Mariani V, Giannetti A, Girolomoni G, Pastore S. House dust mite allergen exerts no direct proinflammatory effects on human keratinocytes. J Allergy Clin Immunol 2002; 109: 532-8.
85. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-15.
86. Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol 2002; 6: 510-25.
87. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 2003; 111: 1185-99.